Occupation or Discipline – Page 13

Prime Medicine Partners with Bristol Myers Squibb in $3.5B Cell Therapy Deal, Narrows Pipeline Focus

12 months ago talkbio0Tagged BMS, Burning Mouth Syndrome, Cell Therapy, Edit, ex vivo, Gene Modification, Ifosfamide/Methotrexate/Procarbazine protocol, PASSIGE, pipeline, Prime Medicine, Reprioritization, squibb, strategic collaboration, Technology

Prime Medicine, Bristol Myers Squibb (BMS), Cell Therapy, Gene Editing, Prime Editing, PASSIGE Technology, Ex Vivo T-Cell Therapies, Pipeline Reprioritization, Strategic Collaboration

UK Regulator Approves Pharming’s Joenja for Rare Immune Disorder APDS, Leveraging FDA Review

12 months ago talkbio0Tagged APDS, Approved, Immune System Diseases, Infrequent, Joenja, leniolisib, Medicines And Healthcare Products Regulatory Agency, Molecular Farming, pamidronate, Review [Publication Type], United States Food and Drug Administration

Joenja, leniolisib, APDS, MHRA approval, FDA review, rare immune disorder, Pharming

Cereno’s CS1 Shows Promising Results in Reducing PAH Risks in Phase 2 Trial

12 months ago talkbio0Tagged Cereno, disease-modifying, Epigenetic modulation, HDAC9 gene, Inhibitor, Phase 2 trial, Pulmonary arterial hypertension, Science, SLAMF7 protein, human

Cereno Scientific, CS1, HDAC inhibitor, Pulmonary Arterial Hypertension (PAH), Phase 2 trial, Epigenetic modulation, CardioMEMS HF System, Disease-modifying treatment

Novo Nordisk Partners with NanoVation in $600M Deal for Advanced Genetic Medicine Delivery

12 months ago talkbio0Tagged cardiometabolic diseases, Genetic Medicine, Hereditary Diseases, Lipid Nanoparticles, NanoVation, Nordisk, Technology

Novo Nordisk, NanoVation Therapeutics, Genetic Medicine, Lipid Nanoparticle (LNP) Technology, Cardiometabolic Diseases, Rare Genetic Disorders

Novo Nordisk and NanoVation Collaborate on $600M Genetic Medicine Deal for Rare and Cardiometabolic Diseases

12 months ago talkbio0Tagged base-editing therapies, cardiometabolic diseases, Genetic Medicine, lipid nanoparticle technology, NanoVation, Nordisk, Obstetric Delivery, RNA

Novo Nordisk, NanoVation, genetic medicine, lipid nanoparticle technology, cardiometabolic diseases, rare diseases, RNA delivery, base-editing therapies

Revolutionizing Drug Discovery: AI-Driven Solutions for Efficient and Personalized Treatments

12 months ago talkbio0Tagged Artificial Intelligence, Computation (action), Drug Development, Drug Discovery, Efficient, Identification (Psychology), Machine Learning, Machine Learning, Pharmaceutical Research, Precision Medicine, processes, QML, quantum, Quantum Machine Learning, Target, Validation

Artificial Intelligence (AI) in Drug Discovery, Machine Learning (ML) for Drug Development, Quantum Computing in Pharmaceutical Research, Personalized Medicine, Efficient Drug Discovery Processes, AI-Driven Target Identification and Validation, Quantum Machine Learning (QML) for Drug Discovery

Roche Secures FDA Approval for Subcutaneous Tecentriq Hybreza, Enhancing Cancer Treatment Options

12 months ago talkbio0Tagged Approved, Enhanze Drug Delivery, Halozyme, Hybreza, Immunotherapy for cancer, Inhibitor, PD-L1, Roche (company), subcutaneous administration, Tecentriq, Technology, United States Food and Drug Administration

Roche, FDA Approval, Tecentriq Hybreza, Subcutaneous Administration, Cancer Immunotherapy, PD-L1 Inhibitor, Halozyme Therapeutics, Enhanze Drug Delivery Technology